ASH23: Jennifer Brown, MD, PhD, discusses ALPINE trial | Dana-Farber Cancer Institute
ASH23: Katie Maurer, MD, PhD, on immune system features and CAR-T | Dana-Farber Cancer Institute
ASH23: Revumenib Monotherapy in RR KMT2Ar Acute Leukemia: Efficacy & Safety Results from the Piv...
ASH23: Andrew Hantel, MD, discusses clinical trial disparities | Dana-Farber Cancer Institute
ASH23: Elizabeth Lightbody, PhD, potential markers multiple myeloma | Dana-Farber Cancer Institute
ASH23: Iceland’s iStopMM Study on Free Light Chains and MGUS | Thorir Einarsson Long, MD, PhD
ASH23: Corey Cutler, MD, MPH, on GVHD and stem cell transplant | Dana-Farber Cancer Institute
Аш 23 - RAPSTAR (MUSIC VIDEO)
ASH23: Corey Cutler, MD, MPH, on AGAVE-201 | Dana-Farber Cancer Institute
ASH23: Paul Richardson, MD, discusses MEZI trial | Dana-Farber Cancer Institute
ASH23: Omar Nadeem, MD, discusses Immuno-PRISM trial | Dana-Farber Cancer Institute
ASH23: Reid Merryman, MD, on ct-DNA & diffuse large B-cell lymphoma | Dana-Farber Cancer Institute
Аш 23 - Сабантуй (Премьера клипа, 2022)
ASH23: Andrew Hantel, MD, discusses artificial intelligence | Dana-Farber Cancer Institute
ASH23: RVd Alone vs Rvd + ASCT in Newly Diagnosed African American MM Patients | Paul Richardson, MD
ASH23: Shai Shimony, MD, molecular ontogeny in AML | Dana-Farber Cancer Institute
ASH23: Post ASH Summary | Joseph Mikhael, MD
Myeloproliferative Neoplasms: Presentation Highlights with Dr Kristen Marie Pettit at ASH23
ASH23: Frontline Treatment DRd vs. VRd for Transplant-Ineligible Myeloma Patients | Doris Hansen, MD
